Skip to main content

Table 1 Summary of patient clinical and pathologic information for cohorts 1 and 2 from Mayo Clinic

From: Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer

 

Cohort 1

Cohort 2

Inter-cohort

 

LTS (n = 22)

STS (n = 14)

P value*

LTS (n = 30)

STS (n = 27)

P value*

LTS

STS

Age (years)

68.5

68.1

0.779

67

64

0.728

0.334

0.401

Sex (males)

15 (68.18%)

12 (86%)

0.236

21 (70%)

14 (51.85%)

0.160

0.887

0.033

SSIGN score (0/1/2/3)

2/2/4/14

3/4/2/5

0.567**

6/7/2/15

8/4/2/13

0.905**

0.567**

0.924**

Stage (1/2/3/4)

20/0/2/0

12/0/2/0

0.999**

20/8/1/1

20/7/0/0

0.994**

0.169**

0.284

Tumor size (cm)

5

4.5

0.373

4.75

4.3

0.711

0.911

0.507

Grade (1/2/3/4)

0/6/16/0

0/5/9/0

0.962

2/14/14/0

3/14/10/0

0.985**

0.550

0.663

Necrosis (yes)

3 (13.64%)

1 (7.14%)

0.999***

1 (3.33%)

3 (11.11%)

0.336***

0.299***

1.000***

  1. Values of continuous variables are displayed as median
  2. Inter-cohort section shows the P values of the analysis of LTScohort 1 versus LTScohort 2, and STScohort 1 versus STScohort 2
  3. *P value of the non-parametric Wilcoxon rank test for continuous data and χ2 for categorical data
  4. **P value resulting from using a Yates χ2 test
  5. ***P value resulting from using a 2 × 2 Fisher’s test